Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neurokin has received the support from the Agence Nationale de la Recherche (ANR) on its Strokinin project aiming at improving the development of NK-102, a neuroprotective drug for the treatment of stroke.
Subscribe to our email newsletter
The neuroprotective efficacy of NK-102 is based on its dual mechanism of action. After a brain injury NK-102, firstly blocks neuronal apoptosis and also reduces inflammation by inhibiting the proliferation of glial cells.
Neurokin said that the 36 months duration project with a global budget of EUR1.5m is supported by a grant of € 813 K€ with 350 K€ attributed to Neurokin.
The project coordinated by Benedicte MENN, co-founder of Neurokin, constitutes a partnership agreement between Neurokin and two INSERM units.
INSERM U615 supplies specific know how in genetics and functional genomics.
For its part, Neurokin supports coordination, additional studies of pharmacology in rats and regulatory development both internally and externally, based on its unique expertise around the NK molecules.
The proof of concept already obtained by the company on the NK-102 will be deepened and a translational approach to development will be implemented.
This will allow dealing with clinical development in 2012, using the necessary tools for the selection and monitoring of patients intended for the establishment of proof of concept in humans in Phase II.
Neurokin CEO Jerome Becquart said that they are very pleased that the ANR has decided to finance and support the program that we run because combined with our ongoing fundraising, this funding will give us the means to pursue more effectively the development of our projects in stroke.